Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Syncom Formulations (India) Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a strong recent price rally, the company’s valuation now demands closer scrutiny against its historical averages and peer group benchmarks within the Pharmaceuticals & Biotechnology sector.

Syncom Formulations (India) Ltd. reported a robust 42.28% year-on-year surge in net profit to ₹25.17 crores for Q4 FY26, marking its strongest quarterly performance in recent history. However, the headline numbers conceal troubling undercurrents: a 9.05% revenue decline compared to the previous year, heavy reliance on non-operating income, and a five-year sales contraction that raises serious questions about the company's core business vitality. Trading at ₹14.33 with a market capitalisation of ₹1,346 crores, the micro-cap pharmaceutical manufacturer faces mounting investor scepticism as the stock has surrendered 27.44% over the past year.

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Syncom Formulations (India) Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a strong day gain of 7.02%, the stock’s overall momentum and technical indicators present a nuanced picture that investors should carefully analyse.

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Despite a broader market rebound, Syncom Formulations (India) Ltd has succumbed to selling pressure, hitting a fresh 52-week low of Rs 10.45 on 30 Mar 2026. The stock’s recent decline contrasts sharply with the market’s tentative recovery, underscoring company-specific challenges that continue to weigh on investor sentiment.

Syncom Formulations (India) Ltd’s stock price declined sharply on 27 Mar 2026, hitting a new 52-week low of Rs.10.97. This marks a significant downturn for the pharmaceutical company amid broader market weakness and persistent challenges reflected in its financial and technical indicators.

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

While the broader market showed signs of recovery, Syncom Formulations (India) Ltd slipped to a fresh 52-week low of Rs 11.05 on 24 Mar 2026, extending a downward trajectory that has seen the stock lose nearly 38% over the past year.

Syncom Formulations (India) Ltd’s stock price declined sharply to a new 52-week low of Rs.11.28 on 23 March 2026, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector amid broader market weakness.

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s performance and outlook.